Clinical Trials | January 24, 2022
RaphaCure partners with Madhavbaug for cardiac healthcare services
Madhavbaug has a pan-India presence with a vast network of 272 clinics and two hospitals
Madhavbaug has a pan-India presence with a vast network of 272 clinics and two hospitals
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
_256_384.jpg)
Extending nonsurgical treatment options for Failing Pulmonic Valve in patients with congenital heart disease using Transcatheter Pulmonary Valve
The facility at the Andhra Pradesh Medtech Zone is expected to be completed by Dec 2022
The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
The country’s top heart transplant surgeon Dr. K.R Balakrishnan to be leading the programme for Jaslok
It is estimated that one-third of our country’s population has some form of these disorders
Forty-two per cent Indian patients with Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) described “confusion about what I was supposed to do next” as an important barrier to early and accurate diagnosis
_256_384.png)
Cryoballoon catheter ablation, a minimally invasive procedure, is one of the therapeutic modalities to manage Atrial fibrillation
The process is completed with the help of a balloon at a low temperature so that other cells are undamaged and the patient can return home the next day
Subscribe To Our Newsletter & Stay Updated
